Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05684965 · ClinicalTrials.gov registry record · Phase 1
XTX301 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Xilio Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 358
- Enrollment target
- 11
- Study locations
NCT05684965 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Xilio Development. The registered enrollment target is 358 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (87% higher). The trial reports 11 study locations across 9 states.
The verdict
NCT05684965, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Xilio Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 358 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG XTX301
Study Locations (11)
Ohio
- The Gabrail Pharmacology Phase 1 Research Center - Canton
- University Hospital Cleveland Medical Center - Cleveland
- The Ohio State University Wexner Medical Center - Columbus
California
- University of California, Davis Comprehensive Cancer Center - Sacramento
Connecticut
- Yale Cancer Center - New Haven
Minnesota
- HealthPartners Frauenshuh Cancer center - Saint Louis Park
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- Hackensack University Medical Center - Hackensack
Pennsylvania
- University of Pittsburgh Medical Center-Hillman Cancer Center - Pittsburgh
Texas
- Tranquil Clinical Research - Webster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2023-05-11 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05684965
The ClinicalTrials.gov registry entry for NCT05684965 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 358 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (87% higher). The listed sponsor is Xilio Development, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which XTX301 is the first listed.
NCT05684965 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Ohio, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05684965 about?
NCT05684965 is a clinical study titled "XTX301 in Patients With Advanced Solid Tumors". This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
What is the current status of trial NCT05684965?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 358 participants. The study started on 2023-05-11. Estimated completion is 2027-02.
What conditions does trial NCT05684965 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT05684965?
The interventions under investigation include: XTX301 (DRUG).
Who is sponsoring clinical trial NCT05684965?
This trial is sponsored by Xilio Development, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05684965 being conducted?
This trial has 11 study locations across California, Connecticut, Minnesota, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.